iTeos Therapeutics (ITOS) Competitors $10.11 -0.02 (-0.20%) Closing price 04:00 PM EasternExtended Trading$10.12 +0.01 (+0.05%) As of 04:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ITOS vs. JANX, ABCL, EVO, EWTX, ANIP, NTLA, ETNB, VERA, BHVN, and COGTShould you be buying iTeos Therapeutics stock or one of its competitors? The main competitors of iTeos Therapeutics include Janux Therapeutics (JANX), AbCellera Biologics (ABCL), Evotec (EVO), Edgewise Therapeutics (EWTX), ANI Pharmaceuticals (ANIP), Intellia Therapeutics (NTLA), 89BIO (ETNB), Vera Therapeutics (VERA), Biohaven (BHVN), and Cogent Biosciences (COGT). These companies are all part of the "pharmaceutical products" industry. iTeos Therapeutics vs. Its Competitors Janux Therapeutics AbCellera Biologics Evotec Edgewise Therapeutics ANI Pharmaceuticals Intellia Therapeutics 89BIO Vera Therapeutics Biohaven Cogent Biosciences iTeos Therapeutics (NASDAQ:ITOS) and Janux Therapeutics (NASDAQ:JANX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings. Does the media favor ITOS or JANX? In the previous week, iTeos Therapeutics had 2 more articles in the media than Janux Therapeutics. MarketBeat recorded 6 mentions for iTeos Therapeutics and 4 mentions for Janux Therapeutics. iTeos Therapeutics' average media sentiment score of -0.45 beat Janux Therapeutics' score of -0.52 indicating that iTeos Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iTeos Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Janux Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Do institutionals & insiders have more ownership in ITOS or JANX? 97.2% of iTeos Therapeutics shares are owned by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are owned by institutional investors. 12.5% of iTeos Therapeutics shares are owned by company insiders. Comparatively, 8.1% of Janux Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has more volatility & risk, ITOS or JANX? iTeos Therapeutics has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500. Comparatively, Janux Therapeutics has a beta of 2.86, indicating that its share price is 186% more volatile than the S&P 500. Which has better valuation & earnings, ITOS or JANX? Janux Therapeutics has lower revenue, but higher earnings than iTeos Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than iTeos Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioiTeos Therapeutics$35M11.05-$134.41M-$3.04-3.33Janux Therapeutics$9.34M144.70-$68.99M-$1.36-16.79 Do analysts recommend ITOS or JANX? iTeos Therapeutics currently has a consensus price target of $15.50, indicating a potential upside of 53.31%. Janux Therapeutics has a consensus price target of $91.89, indicating a potential upside of 302.49%. Given Janux Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Janux Therapeutics is more favorable than iTeos Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score iTeos Therapeutics 0 Sell rating(s) 6 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.14Janux Therapeutics 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 3.08 Is ITOS or JANX more profitable? Janux Therapeutics' return on equity of -9.29% beat iTeos Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets iTeos TherapeuticsN/A -31.85% -27.48% Janux Therapeutics N/A -9.29%-8.89% SummaryJanux Therapeutics beats iTeos Therapeutics on 10 of the 16 factors compared between the two stocks. Get iTeos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ITOS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ITOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ITOS vs. The Competition Export to ExcelMetriciTeos TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$386.91M$2.98B$5.45B$9.68BDividend YieldN/A2.46%3.99%4.14%P/E Ratio-2.1617.9230.1125.01Price / Sales11.05178.92379.2478.79Price / CashN/A41.8335.9458.58Price / Book0.637.268.135.68Net Income-$134.41M-$54.43M$3.26B$265.68M7 Day Performance0.20%-0.01%1.15%2.51%1 Month Performance-0.10%5.13%2.82%1.88%1 Year Performance-32.49%10.24%28.41%24.00% iTeos Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ITOSiTeos Therapeutics2.9397 of 5 stars$10.11-0.2%$15.50+53.3%-33.4%$386.91M$35M-2.1690News CoverageEarnings ReportAnalyst ForecastJANXJanux Therapeutics1.9247 of 5 stars$25.55-1.6%$91.89+259.6%-36.0%$1.54B$10.59M-18.7930Earnings ReportABCLAbCellera Biologics3.2302 of 5 stars$4.92-3.7%$8.75+77.8%+61.2%$1.52B$23.11M-8.79500News CoverageEarnings ReportAnalyst ForecastGap UpEVOEvotec2.3029 of 5 stars$4.26flat$5.93+39.3%+26.1%$1.51B$788.22M0.004,827Upcoming EarningsGap UpEWTXEdgewise Therapeutics2.0013 of 5 stars$14.26+1.0%$40.00+180.5%-18.5%$1.49BN/A-9.2060News CoverageEarnings ReportAnalyst ForecastANIPANI Pharmaceuticals3.2214 of 5 stars$66.50-1.5%$78.88+18.6%+21.0%$1.46B$614.38M-52.36600Trending NewsEarnings ReportAnalyst ForecastGap UpNTLAIntellia Therapeutics4.5843 of 5 stars$13.11-3.6%$33.37+154.5%-46.2%$1.41B$57.88M-2.51600News CoverageEarnings ReportAnalyst ForecastETNB89BIO1.9692 of 5 stars$9.53-0.6%$26.43+177.3%+17.0%$1.40BN/A-2.8240News CoveragePositive NewsEarnings ReportAnalyst ForecastVERAVera Therapeutics3.0778 of 5 stars$20.87-4.3%$65.00+211.5%-44.7%$1.39BN/A-6.9640Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionBHVNBiohaven2.3439 of 5 stars$13.10-3.0%$58.46+346.3%-55.8%$1.38BN/A-1.40239Upcoming EarningsCOGTCogent Biosciences3.0349 of 5 stars$12.09+0.2%$18.70+54.7%+25.8%$1.37BN/A-6.5780Trending NewsEarnings ReportAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies JANX Competitors ABCL Competitors EVO Competitors EWTX Competitors ANIP Competitors NTLA Competitors ETNB Competitors VERA Competitors BHVN Competitors COGT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ITOS) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredGreen Light for These StocksGuess Who Washington Will Partner With Next? The U.S. government just made a bold $400 million move... beco...Stansberry Research | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iTeos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share iTeos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
